Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN003 vs Chemotherapy in HER2-low Metastatic Breast Cancer
NCT06079983Phase 3Recruiting
- Sponsor
- Alphamab Oncology
- Start
- Dec 2023
- Primary completion
- Apr 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of anbenitamab repodatecan in breast cancer, sponsored by Alphamab Oncology. Started Dec 2023; status: recruiting.
02
Drugs
anbenitamab repodatecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06079983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079983.